Overactive Bladder

First-in-Class Opportunity

OptMed genitourinary therapeutics
OAB or increased urinary urgency, affects more than 16 million women in the U.S. alone. OAB significantly affects quality of life, including sleep and sexual function. OAB is believed to result from inappropriate, nonurination-related contractions of the detrusor muscle that surrounds the bladder. Current treatments for OAB are antimuscarinic drugs, which are not uniformly effective, and all have typical anticholinergic side effects such as dry mouth, blurred vision, confusion, constipation, etc. It is estimated that up to 60 percent of patients discontinue treatment within one year due to side effects. Despite these shortcomings, these drugs generated $3 billion in global revenues in 2008.

Preclinical Data

OptMed has conducted extensive preclinical studies in OAB animal models that demonstrated strong preclinical proof-of-concept. In rat studies, intravaginal delivery of valium significantly reduced the spontaneous detrusor muscle contractions and the frequent need to urinate linked to overactive bladder. It also showed that local administration did not result in clinically significant levels of drug in the bloodstream.
OptMed's OAB therapeutic is a potential first-in-class drug that may relieve urinary urgency through targeted relaxation of the detrusor muscle.